Yahoo Finance

Zilucoplan: A Selective C5 (Complement Component 5) Peptide Inhibitor Under Clinical Development by UCB Biopharma - Emerging Drug Insight and Market Forecasts to 2032

Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Zilucoplan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides ...
PharmiWeb

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
Yahoo Finance

EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for ...

WATERTOWN, Mass. and NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve ...
MedPage Today

In NMOSD, Could Inhibiting Complement C5a Help Reduce Pain?

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
PR Newswire

Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsight

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...